Development of albumin-binding camptothecin prodrugs using a peptide positional scanning library

Bioconjugate Chemistry

Volumn 18, Issue 6, 2007, Pages 1786-1799

  Schmid, Björn ^a   Warnecke, André ^a   Fichtner, Iduna ^b   Jung, Manfred ^c   Kratz, Felix ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BODY FLUIDS; CHEMOTHERAPY; DIAGNOSIS; PEPTIDES;

ALBUMIN BINDINGS; AMINO-ACIDS; CAMPTOTHECINS; CANCER CHEMOTHERAPY; HUMAN COLON; PEPTIDE LINKERS; PEPTIDE SEQUENCES; PRODRUGS; SPECTRA'S; TUMOUR XENOGRAFTS;

TUMORS;

6 MALEIMIDOCAPROIC ACID ARGINYLARGINYLALANYLPHENYLALANYLMETHIONYLALANINE CAMPTOTHECIN; 6 MALEIMIDOCAPROIC ACID ARGINYLARGINYLPHENYLALANYLTYROSYLMETHIONYLALANINE CAMPTOTHECIN; ALBUMIN; ARGININE; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; LEUCINE; LYSINE; METHIONINE; PEPTIDE LIBRARY; PHENYLALANINE; PRODRUG; TYROSINE; UNCLASSIFIED DRUG; WATER;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; CELL STRAIN HT29; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG SOLUBILITY; HUMAN; HUMAN CELL; KIDNEY HOMOGENATE; LIVER HOMOGENATE; MOUSE; NONHUMAN; PH; SCREENING; SPLEEN; TISSUE HOMOGENATE; TUMOR XENOGRAFT;

MURINAE;

EID: 36849072730     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc0700842     Document Type: Article

References (44)

1. Matsumura, Y., and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387-6392.
2. Haag, R., and Kratz, F. (2006) Polymer therapeutics: concepts and applications. Angew. Chem., Int. Ed. Engl. 45, 1198-1215.
3. Kratz, F., Warnecke, A., Scheuermann, K., Stockmar, C., Schwab, J., Lazar, P., Druckes, P., Esser, N., Drevs, J., Rognan, D., Bissantz, C., Hinderung, C., Folkers, G., Fichtner, I., and Unger, C. (2002) Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives: improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J. Med. Chem. 45, 5523-5533.
4. Kratz, F., Muller-Driver, R., Hofmann, I., Drevs, J., and Unger, C. (2000) A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J. Med. Chem. 43, 1253-1256.
5. Kratz, F., Warnecke, A., Scheuermann, K., Stockmar, C., Schwab, J., Lazar, P., Druckes, P., Esser, N., Drevs, J., Rognan, D., Bissantz, C., Hinderung, C., Folkers, G., Fichtner, I., and Unger, C. (2002) Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J. Med. Chem. 45, 5523-5533.
6. Mansour, A. M., Drevs, J., Esser, N., Hamada, F. M., Badary, O. A., Unger, C., Fichtner, I., and Kratz, F. (2003) A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res. 63, 4062-4066.
7. Kratz, F., Mansour, A., Soltau, J., Warnecke, A., Fichtner, I., Unger, C., and Drevs, J. (2005) Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen. Arch. Pharm. (Weinheim) 338, 462-472.
8. Chung, D. E., and Kratz, F. (2006) Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA). Bioorg. Med. Chem. Lett. 16, 5157-5163.
9. Warnecke, A., Fichtner, I., Garmann, D., Jaehde, U., and Kratz, F. (2004) Synthesis and biological activity of water-soluble maleimide derivatives of the anticancer drug carboplatin designed as albumin-binding prodrugs. Bioconjugate Chem. 15, 1349-1359.
10. Warnecke, A., and Kratz, F. (2003) Maleimide-oligo(ethylene glycol) derivatives of camptothecin as albumin-binding prodrugs: synthesis and antitumor efficacy. Bioconjugate Chem. 14, 377-387.
11. Kratz, F. (2007) DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials. Exp. Opin. Invest. Drugs 16, 855-866.
12. Goel, A., and Chauhan, S. S. (1997) Role of proteases in tumor invasion and metastasis. Ind. J. Exp. Biol. 35, 553-564.
13. Ruppert, C., Ehrenforth, S., Scharrer, I., and Halberstadt, E. (1997) Protease levels in breast, ovary, and other gynecological tumor tissues: prognostic importance in breast cancer. Cancer Detect. Prev. 21, 452-459.
14. Decock, J., Paridaens, R., and Cufer, T. (2005) Proteases and metastasis: clinical relevance nowadays? Curr. Opin. Oncol. 17, 545-50.
15. Jedeszko, C., and Sloane, B. F. (2004) Cysteine cathepsins in human cancer. Biol Chem 385, 1017-27.
16. Fingleton, B. (2006) Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci 11, 479-91.
17. Dano, K., Behrendt, N., Hoyer-Hansen, G., Johnsen, M., Lund, L. R., Ploug, M., and Romer, J. (2005) Plasminogen activation and cancer. Thromb. Haemost. 93, 676-81.
18. Partin, A. W., Hanks, G. E., Klein, E. A., Moul, J. W., Nelson, W. G., and Scher, H. I. (2002) Prostate-specific antigen as a marker of disease activity in prostate cancer. Oncology (Williston Park) 16, 1218-24, discussion 1224, 1227-8 passim.
19. Kratz, F., Drevs, J., Bing, G., Stockmar, C., Scheuermann, K., Lazar, P., and Unger, C. (2001) Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates. Bioorg. Med. Chem. Lett. 11, 2001-2006.
20. Wall, M. E., Wani, M. C., Cook, C. E., and Palmer, K. H. (1966) Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminata. J. Am. Chem. Soc. 88, 3888-3890.
21. Hsiang, Y.-H., Hertzberg, R., Hecht, S., and Liu, L. F. (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260, 14873-14878.
22. Kingsbury, W., Boehm, J., Jakas, D., Holden, K., Hecht, S., Gallagher, G., Caranfa, M., McCabe, F., Faucette, L., Johnson, R., and Hertzberg, R. (1991) Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J. Med. Chem. 34, 98-107.
23. Kollmannsberger, C., Mross, K., Jakob, A., Kanz, L., and Bokemeyer, C. (1999) Topotecan - a novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology 56, 1-12.
24. Rothenberg, M. L. (2001) Irinotecan (CPT-11): recent developments and future directions - colorectal cancer and beyond. Oncologist 6, 66-80.
25. Greenwald, R. B., Pendri, A., and Zhao, H. (1998) Stereose-lective acylation of 20-(S)-camptothecin with amino acid derivatives using scandium triflate/DMAP. Tetrahedron Asymm. 9, 915-918.
26. Harris, J. L., Backes, B. J., Leonetti, F., Mahrus, S., Ellman, J. A., and Craik, C. S. (2000) Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. Proc. Natl. Acad. Sci. U.S.A. 97, 7754-7759.
27. Backes, B. J., Harris, J. L., Leonetti, F., Craik, C. S., and Ellman, J. A. (2000) Synthesis of positional-scanning libraries of fluorogenic peptide substrates to define the extended substrate specificity of plasmin and thrombin. Nat. Biotechnol. 18, 187-193.
28. Maly, D. J., Leonetti, F., Backes, B. J., Dauber, D. S., Harris, J. L., Craik, C. S., and Ellman, J. A. (2002) Expedient solid-phase synthesis of fluorogenic protease substrates using the 7-amino-4-carbamoylmethylcoumarin (ACC) fluorophore. J. Org. Chem. 67, 910-915.
29. Chan, W. C., and White, P. D. (2000) In The practical approach series (Hames, B. D., Ed.).
30. Ostresh, J. M., Winkle, J. H., Hamashin, V. T., and Houghten, R. A. (1994) Peptide libraries: determination of relative reaction rates of protected amino acids in competitive couplings. Biopolymers 34, 1681-1689.
31. Werle, B., Ebert, W., Klein, W., and Spiess, E. (1994) Cathepsin B in tumors, normal tissue and isolated cells from the human lung. Anticancer Res. 14, 1169-1176.
32. Duffy, M. J., Blaser, J., Duggan, C., McDermott, E., O'Higgins, N., Fennelly, J. J., and Tschesche, H. (1995) Assay of matrix metalloproteases types 8 and 9 by ELISA in human breast cancer. Br. J. Cancer 71, 1025-1028.
33. Richardson, P. L. (2002) The determination and use of optimized protease substrates in drug discovery and development. Curr. Pharm. Des. 8, 2559-2581.
34. Thornberry, N. A., Rano, T. A., Peterson, E. P., Rasper, D. M., Timkey, T., Garcia-Calvo, M., Houtzager, V. M., Nordstrom, P. A., Roy, S., Vaillancourt, J. P., Chapman, K. T., and Nicholson, D. W. (1997) A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J. Biol. Chem. 272, 17907-11.
35. Choe, Y., Leonetti, F., Greenbaum, D. C., Lecaille, F., Bogyo, M., Bromme, D., Ellman, J. A., and Craik, C. S. (2006) Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities. J. Biol. Chem. 281, 12824-32.
36. Rowinsky, E. K., Rizzo, J., Ochoa, L., Takimoto, C. H., Forouzesh, B., Schwartz, G., Hammond, L. A., Patnaik, A., Kwiatek, J., Goetz, A., Denis, L., McGuire, J., and Tolcher, A. W. (2003) A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. J. Clin. Oncol. 21, 148-157.
37. Conover, C. D., Greenwald, R. B., Pendri, A., and Shum, K. L. (1999) Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs. Anti-Cancer Drug Design 14, 499-506.
38. Greenwald, R. B., Pendri, A., Conover, C. D., Lee, C., Choe, Y. H., Gilbert, C., Martinez, A., Xia, Y., Wu, D., and Hsue, M. (1998) Camptothecin-20-PEG ester transport forms: the effect of spacer groups on antitumor activity. Bioorg. Med. Chem. 6, 551-562.
39. Liu, X., Zhang, J., Song, L., Lynn, B. C., and Burke, T. G. (2004) Degradation of camptothecin-20(S)-glycinate ester prodrug under physiological conditions. J. Pharm. Biomed. Anal. 35, 1113-1125.
40. Song, L., Bevins, R., and Anderson, B. D. (2006) Kinetics and mechanisms of activation of alpha-amino acid ester prodrugs of camptothecins. J. Med. Chem. 49, 4344-4355.
41. Mansour, A. M., Drevs, J., Esser, N., Hamada, F. M., Badary, O. A., Unger, C., Fichtner, I., and Kratz, F. (2003) A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res. 63, 4062-4066.
42. Kratz, F., Mansour, A., Soltau, J., Warnecke, A., Fichtner, I., Unger, C., and Drevs, J. (2005) Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen (PSA). Arch. Pharm. 338, 462-472.
43. Caiolfa, V. R., Zamai, M., Fiorino, A., Frigerio, E., Pellizzoni, C., d'Argy, R., Ghiglieri, A., Castelli, M. G., Farao, M., Pesenti, E., Gigli, M., Angelucci, F., and Suarato, A. (2000) Polymerbound camptothecin: initial biodistribution and antitumour activity studies. J. Controlled Release 65, 105-119.
44. Choe, Y., Leonetti, F., Greenbaum, D. C., Lecaille, F., Bogyo, M., Bromme, D., Ellman, J. A., and Craik, C. S. (2006) Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities. J. Biol. Chem. 281, 12824-12832.